The estimated Net Worth of Michael R Megna is at least $651 Mille dollars as of 15 July 2024. Mr. Megna owns over 7,265 units of Kiniksa Pharmaceuticals International Plc stock worth over $651,436 and over the last 5 years he sold KNSA stock worth over $0. In addition, he makes $0 as Principal Financial Officer e Chief Accounting Officer at Kiniksa Pharmaceuticals International Plc.
Michael has made over 14 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,265 units of KNSA stock worth $176,830 on 15 July 2024.
The largest trade he's ever made was exercising 16,670 units of Kiniksa Pharmaceuticals International Plc stock on 2 January 2024 worth over $231,380. On average, Michael trades about 3,238 units every 67 days since 2020. As of 15 July 2024 he still owns at least 26,764 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr. Megna stock trades at the bottom of the page.
Michael R. Megna serves as Principal Financial Officer, Chief Accounting Officer of the Company. He oversees the company’s accounting and finance functions. From July 2012 until July 2018, Mr. Megna served in roles of increasing seniority at LFB USA, Inc./rEVO Biologics, Inc., a biopharmaceutical company, most recently as Senior Vice President, Finance & Accounting. In those roles, Mr. Megna oversaw finance, IT, human resources and project management functions. Mr. Megna received his bachelor’s of business administration from Siena College. Mr. Megna is also a Certified Public Accountant.
Michael Megna is 49, he's been the Principal Financial Officer e Chief Accounting Officer of Kiniksa Pharmaceuticals International Plc since 2020. There are 14 older and 1 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
Michael's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... e Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include: